PT  - JOURNAL ARTICLE
AU  - Essex, Morgan
AU  - Rios Rodriguez, Valeria
AU  - Rademacher, Judith
AU  - Proft, Fabian
AU  - Löber, Ulrike
AU  - Markó, Lajos
AU  - Pleyer, Uwe
AU  - Strowig, Till
AU  - Marchand, Jérémy
AU  - Kirwan, Jennifer A.
AU  - Siegmund, Britta
AU  - Forslund, Sofia Kirke
AU  - Poddubnyy, Denis
TI  - Spondyloarthritis, acute anterior uveitis, and Crohn’s disease have both shared and distinct gut microbiota
AID  - 10.1101/2022.05.13.22275044
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.05.13.22275044
4099  - http://medrxiv.org/content/early/2023/05/28/2022.05.13.22275044.short
4100  - http://medrxiv.org/content/early/2023/05/28/2022.05.13.22275044.full
AB  - Objectives Spondyloarthritis (SpA) is a group of immune-mediated diseases highly concomitant with non-musculoskeletal inflammatory disorders, such as acute anterior uveitis (AAU) and Crohn’s disease (CD). The gut microbiome represents a promising avenue to elucidate shared and distinct underlying pathophysiology.Method We performed 16S rRNA sequencing on stool samples of 277 patients (72 CD, 103 AAU, and 102 SpA) included in the German Spondyloarthritis Inception Cohort (GESPIC) and 62 back pain controls without any inflammatory disorder. Discriminatory statistical methods were used to disentangle microbial disease signals from one another and a wide range of potential confounders. Patients were naïve to or had not received treatment with biological disease-modifying anti-rheumatic drugs for at least three months before enrollment, providing a better approximation of a true baseline disease signal.Results We identified a shared, immune-mediated disease signal represented by low abundances of Lachnospiraceae taxa relative to controls, most notably Fusicatenibacter, which partially mediated higher serum CRP levels and was most abundant in controls receiving NSAID monotherapy. Patients with SpA drove an enrichment of Collinsella, while HLA-B27+ individuals displayed enriched Faecalibacterium. CD patients had higher abundances of a Ruminococcus taxon, and previous csDMARD therapy was associated with increased Akkermansia.Conclusion Our work supports the existence of a common gut dysbiosis in SpA and related inflammatory pathologies. We reveal shared and disease-specific microbial associations and potential mediators of disease activity. Validation studies are needed to clarify the role of Fusicatenibacter in gut-joint inflammation, and metagenomic resolution is needed to understand the relationship between Faecalibacterium commensals and HLA-B27.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) as part of a clinical research unit (CRU339): Food allergy and tolerance (FOOD@), Project No. 428046232 and CRC-TRR241 and CRC1449 to B.S. T.S. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy, EXC 2155 "RESIST", Project ID 39087428. Additional funding was received from the German Federal Ministry for Health and Research (BMBF) as part of the WHEAT-A-BAIC consortium, and from the Berlin Institute of Health (BIH). The OptiRef control cohort was partially supported from an unrestricted research grant from Novartis, and the AAU cohort by a grant from AbbVie.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical committee of Charité-Universitätsmedizin Berlin gave ethical approval for this work, and all patients gave their written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/sxmorgan/gespic-public https://github.com/sxmorgan/gespic-public